Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. Those treatments present a large market potential and broad applicability in solid tumors. Ymmunobio is making extensive progress in developing antibodies that have unique features of fighting cancers.
Company Details
- Employees
- 6
- Founded
- 2021
- Address
- Basel, Basel 4125, Ch
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.ymmuno.bio
- Keywords
- NXI Therapeutics AG.
- HQ
- Basel, Basel
Ymmunobio Questions
Ymmunobio's website is https://www.ymmuno.bio
Ymmunobio's LinkedIn profile is https://www.linkedin.com/company/ymmunobio-ag
Ymmunobio has
6 employees.
View email and phone details for 6
employees at Ymmunobio.
Ymmunobio's industry is
Biotechnology Research
Ymmunobio's top competitors are
Allegria Therapeutics,
Eviive Ag,
Nxi Therapeutics Ag,
Widler & Schiemann Ag,
Amyra Biotech Ag,
Adoram Therapeutics,
Synendos Therapeutics Ag,
Manhattan Biosolutions, Inc.,
Albatroz Therapeutics,
Debiopharm.
Ymmunobio's categories are Biotechnology Research
Ymmunobio's founding year is 2021
